[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605262":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":32,"centralContacts":32,"locations":36,"responsibleParty":137,"collaborators":139,"id":142,"slug":143,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":144,"sex":150,"minAge":151,"maxAge":32,"enrollmentInfo":152,"targetDuration":32,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":39,"whyStopped":32,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Sint Maartenskliniek","OTHER",[8,14,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose reduction group (randomised)","EXPERIMENTAL","disease activity guided dose reduction strategy of JAKi",[13],"Drug: JAKi dose reduction strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group (randomised)","ACTIVE_COMPARATOR","disease activity guided continuation of same dose strategy of JAKi (randomised)",[19],"Drug: JAKi disease activity guided continuation of same dose strategy",{"label":21,"type":10,"description":11,"interventionNames":22},"Dose reduction group (non-randomised)",[13],{"label":24,"type":16,"description":25,"interventionNames":26},"Control group (non-randomised)","disease activity guided continuation of same dose strategy of JAKi",[19],[28,33],{"type":29,"name":30,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","JAKi dose reduction strategy",[21,9],null,{"type":29,"name":34,"description":34,"armGroupLabels":35,"otherNames":32},"JAKi disease activity guided continuation of same dose strategy",[24,15],[37,57,72,86,100,113,127],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sint Maartenskliniek Nijmegen","RECRUITING","Nijmegen","Gelderland","6574 NA","Netherlands","NL",{"type":46,"coordinates":47},"Point",[48,49],5.85278,51.8425,{"lat":49,"lon":48},[52],{"name":53,"role":54,"phone":55,"phoneExt":32,"email":56},"Dr. N. van Herwaarden","CONTACT","+31 24 365 94 09","n.vanherwaarden@maartenskliniek.nl",{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":43,"countryCode":44,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Maastricht UMC+","NOT_YET_RECRUITING","Maastricht","Limburg","6229 HX",{"type":46,"coordinates":64},[65,66],5.68889,50.84833,{"lat":66,"lon":65},[69],{"name":70,"role":54,"phone":32,"phoneExt":32,"email":71},"Prof dr. A. van Tubergen","a.van.tubergen@mumc.nl",{"facility":73,"status":59,"city":74,"state":75,"zip":76,"country":43,"countryCode":44,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Elisabeth-TweeSteden Ziekenhuis Tilburg","Tilburg","North Brabant","5022 GC",{"type":46,"coordinates":78},[79,80],5.0913,51.55551,{"lat":80,"lon":79},[83],{"name":84,"role":54,"phone":32,"phoneExt":32,"email":85},"Dr. L Schipper","l.schipper@etz.nl",{"facility":87,"status":59,"city":88,"state":89,"zip":90,"country":43,"countryCode":44,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Medisch Spectrum Twente","Enschede","Overijssel","7512 KZ",{"type":46,"coordinates":92},[93,94],6.89583,52.21833,{"lat":94,"lon":93},[97],{"name":98,"role":54,"phone":32,"phoneExt":32,"email":99},"Prof dr. H. Vonkeman","h.vonkeman@mst.nl",{"facility":101,"status":59,"city":102,"state":89,"zip":103,"country":43,"countryCode":44,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Isala Zwolle","Zwolle","8025 AB",{"type":46,"coordinates":105},[106,107],6.09444,52.5125,{"lat":107,"lon":106},[110],{"name":111,"role":54,"phone":32,"phoneExt":32,"email":112},"Dr A.E. van der Bijl","a.e.van.der.bijl@isala.nl",{"facility":114,"status":59,"city":115,"state":116,"zip":117,"country":43,"countryCode":44,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Erasmus MC","Rotterdam","South Holland","3015 GD",{"type":46,"coordinates":119},[120,121],4.47917,51.9225,{"lat":121,"lon":120},[124],{"name":125,"role":54,"phone":32,"phoneExt":32,"email":126},"Dr. P.H.P. de Jong","p.h.p.dejong@erasmusmc.nl",{"facility":128,"status":59,"city":115,"state":116,"zip":129,"country":43,"countryCode":44,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"Maasstad ziekenhuis","3079 DZ",{"type":46,"coordinates":131},[120,121],{"lat":121,"lon":120},[134],{"name":135,"role":54,"phone":32,"phoneExt":32,"email":136},"Dr. M. Kok","kokmr@maasstadziekenhuis.nl",{"type":138,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[140],{"name":141,"class":6},"ZonMw: The Netherlands Organisation for Health Research and Development","100605262","phase-4-redo-jak-dose-reduction-of-janus-kinase-inhibitors-in-patients-with-inflammatory-rheumatic-diseases-100605262",false,"NCT07160231","REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK: Dose REDuction Of JAnus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK","Inclusion Criteria:\n\n* Patients ≥ 16 years of age\n* Clinical diagnosis of RA, PsA or axSpA\n* Treated with a JAKi (monotherapy or combination with csDMARDwith a JAKi dose ≥ 50% of the authorised dose)\n* LDA or remission for at least 6 months according to accepted criteria for the specific disease and\u002For the judgement of the treating rheumatologist and patient. (RA: DAS28-CRP \\\u003C 2.9; PsA: PASDAS ≤3.2 and psoriasis mBSA involvement ≤3%; axSpA: ASDAS \\\u003C2.1.)\n\nExclusion Criteria:\n\n* Comorbidity for which continued JAKi treatment is expected to be necessary (e.g. active Crohn's disease, ulcerative colitis)\n* Life expectancy ≤12 months\n* Pregnancy (JAKi are contra-indicated during pregnancy, therefore we do not expect patients using a JAKi while pregnant)\n* Patients who are enrolled in other trials that might mutually interfere\n* Not able to provide informed consent","ALL","16 Years",{"count":153,"type":154},200,"ESTIMATED","INTERVENTIONAL",[157],"PHASE4","The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who are in a state of low disease activity or remission while on JAKi. The main question it aims to answer is:\n\nIs a disease activity guided dose reduction strategy for JAKi not inferior in terms of efficacy compared to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state?\n\nResearchers will compare a disease activity guided dose reduction strategy for JAKi to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state to see if a disease activity guided dose reduction strategy for JAKi is not inferior in terms of efficacy compared to disease activity guided JAKi continuation.\n\nParticipants will:\n\n* Follow a JAKi dose reduction strategy or will continue using JAKi in the same dose\n* Study (telemonitoring) visits are planned every 3 months\n* At every visit, patients are asked to complete patient-reported outcomes that assess daily functioning, health-related quality of life, pain, fatigue, productivity loss, medical consumption and medication adherence.",[160,161,162],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Axial Spondyloarthritis (AxSpA)",[164,165,166],"disease activity guided dose reduction","Janus kinase inhibitors (JAKi)","disease activity guided JAKi continuation","2025-09-16",{"date":169,"type":170},"2025-09-17","ACTUAL",{"date":172,"type":170},"2025-09-15",{"date":174,"type":154},"2028-05-01",{"name":5,"class":6},7]